Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Pediatric acute-onset neuropsychiatric syndrome (PANS) · acute hereditary angioedema attacks · MAZE

Maze Therapeutics

Maze Therapeutics patent portfolio — 60 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
South San Francisco, USA HQ
2018 Founded
152 Employees
Public company Type
MAZE · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Founded
2018
Employees
152
Programs
8
Drugs
12
Patents
60
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Maze Therapeutics patents

60 pharmaceutical patents indexed for Maze Therapeutics. 2 expire within 24 months.

Maze Therapeutics has 60 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 2 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

60 patents

Patent portfolio

Page 1 of 2

  1. US 12310943

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12297182

    Compositions comprising an urolithin compound

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12226455

    Medical composition for treating cardiac wasting and cachexia

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12220424

    Compositions comprising nicotinamide riboside and a urolithin

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12109190

    Urolithins as immune response enhancers

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12036205

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12030863

    Prodrugs of urolithins and uses thereof

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11969408

    Method for improving mitophagy in subjects

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11931335

    Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11931336

    Enhancing autophagy or increasing longevity by administration of urolithins

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11925616

    Compositions comprising urolithin compounds

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11903922

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11878964

    Compositions comprising an urolithin compound

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11566255

    Expression of PEDV sequences in plants and plant produced vaccine for same

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11426380

    Urolithins as immune response enhancers

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11337957

    Compositions comprising urolithin compounds

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11234960

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11180468

    Prodrugs of urolithins and uses thereof

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11166937

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11166972

    Compositions comprising nicotinamide riboside and a urolithin

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11020373

    Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10988453

    Compositions comprising an urolithin compound

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10857126

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10799561

    Method for increasing cardiac inflow by administering a compound that binds RXFP1

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10792276

    Urolithins as immune response enhancers

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10695320

    Compositions comprising urolithin compounds

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10532992

    Prodrugs of urolithins and uses thereof

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10485782

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10442784

    Compositions comprising an urolithin compound

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10265397

    Formulation for photodynamic therapy

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10226512

    Method for treating heart failure with preserved ejection fraction by administering human relaxin-2

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10201609

    Method for the production of a formulation of a hypericin salt

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10143751

    Photodynamic therapy, formulation usable for this purpose, and method for the production and use thereof

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10064961

    Method for producing a liquid pharmaceutical preparation

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10028932

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9994542

    Prodrugs of urolithins and uses thereof

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9980980

    Compounds, compositions and methods for protecting brain health in neurodegenerative disorders

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9962366

    Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9872850

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9775900

    Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9675598

    Compositions of tolperisone

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9662317

    Methods of administering tolperisone for therapeutic purposes

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9629932

    Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof

    Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9573922

    Process-scale synthesis of urolithins

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9394269

    Process-scale synthesis of urolithins

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9315480

    Compositions of tolperisone

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8933217

    Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders

    Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8404869

    Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Maze Therapeutics have?

60 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Maze Therapeutics patents expire?

2 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.